Bortezomib Sensitizes Malignant Human Glioma Cells to TRAIL, Mediated by Inhibition of the NF-κB Signaling Pathway

Esther P. Jane(UPMC Hillman Cancer Center), Ian F. Pollack(University of Pittsburgh)
Molecular Cancer Therapeutics
January 1, 2011
Cited by 75


Related Papers